1. A method for the additional treatment of type II diabetes mellitus, comprising administering to a subject with type II diabetes who has an insufficient reaction to an antidiabetic agent, a therapeutically effective amount of diacerein or its pharmaceutically acceptable salt, analog, prodrug or active metabolite. The method of claim 1, wherein said subject is a type II diabetes patient with a condition selected from the group consisting of insulin resistance, glucose intolerance, hyperglycemia, or hyperinsulinemia. The method of claim 1, wherein said therapeutically effective amount of diacerein is from 25 to 200 mg per day. A method for improving glycemic control in a patient taking an antidiabetic agent, comprising administering to said patient: a) a therapeutically effective amount of diacerein or its pharmaceutically acceptable salt, analogue, prodrug or active metabolite, and b) said antidiabetic agent. 5. The method according to claim 4, wherein said antidiabetic agent is at least one agent selected from the group consisting of sulfonylurea, biguanide, α-glucosidase inhibitor, thiazolidinedione, peroxis proliferator activated receptor agonist, non-dipeptidyl peptidase-4 inhibitor, containing sulfonylurea insulin secretion stimulator, glucagon-like peptide-1 analogue, metformin, glyburide, glimepiride, glypiride, glipizide, chlorpropamide, glycazide, acarbose, miglitol, pioglitazone, t roglitazone, rosiglitazone, isaglitazone, muraglitizar, peliglitazar,1. Способ дополнительного лечения сахарного диабета II типа, включающий введение субъекту с диабетом II типа, у которого существует недостаточная реакция на противодиабетическое средство, терапевтически эффективного количества диацереина или его фармацевтически приемлемой соли, аналога, пролекарства или активного метаболита.2. Способ по п. 1, в котором указанный субъект представляет собой страдающего диабетом II типа пациента с состоянием, выбранным из группы, состоящей из инсулинорезистентности, непереносимос
